BridgeBio Pharma Net Profit Margin 2018-2026 | BBIO
Current and historical net profit margin for BridgeBio Pharma (BBIO) from 2018 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue. BridgeBio Pharma net profit margin for the three months ending June 30, 2026 was .
| BridgeBio Pharma Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2026-06-30 | $0.71B | $-0.69B | -96.92% |
| 2026-03-31 | $0.58B | $-0.72B | -124.27% |
| 2025-12-31 | $0.50B | $-0.73B | -144.14% |
| 2025-09-30 | $0.36B | $-0.80B | -224.51% |
| 2025-06-30 | $0.24B | $-0.78B | -327.43% |
| 2025-03-31 | $0.13B | $-0.67B | -521.09% |
| 2024-12-31 | $0.22B | $-0.54B | -240.99% |
| 2024-09-30 | $0.22B | $-0.44B | -200.92% |
| 2024-06-30 | $0.22B | $-0.45B | -206.85% |
| 2024-03-31 | $0.22B | $-0.54B | -245.66% |
| 2023-12-31 | $0.01B | $-0.64B | -6430.00% |
| 2023-09-30 | $0.01B | $-0.61B | -6130.00% |
| 2023-06-30 | $0.01B | $-0.57B | -9550.00% |
| 2023-03-31 | $0.08B | $-0.43B | -544.87% |
| 2022-12-31 | $0.08B | $-0.48B | -616.67% |
| 2022-09-30 | $0.09B | $-0.49B | -550.56% |
| 2022-06-30 | $0.09B | $-0.51B | -559.34% |
| 2022-03-31 | $0.07B | $-0.60B | -838.03% |
| 2021-12-31 | $0.07B | $-0.56B | -814.49% |
| 2021-09-30 | $0.06B | $-0.54B | -955.36% |
| 2021-06-30 | $0.06B | $-0.50B | -798.39% |
| 2020-09-30 | $0.02B | $-0.40B | -1827.27% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |